Astria Therapeutics/$ATXS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Astria Therapeutics
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
Ticker
$ATXS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
78
ISIN
US04635X1028
Website
ATXS Metrics
BasicAdvanced
$307M
-
-$1.88
0.45
-
Price and volume
Market cap
$307M
Beta
0.45
52-week high
$12.70
52-week low
$3.56
Average daily volume
467K
Financial strength
Current ratio
17.386
Quick ratio
16.932
Long term debt to equity
1.269
Total debt to equity
1.75
Profitability
Management effectiveness
Return on assets (TTM)
-22.56%
Return on equity (TTM)
-32.89%
Valuation
Price to book
1.58
Price to tangible book (TTM)
1.58
Price to free cash flow (TTM)
-3.248
Free cash flow yield (TTM)
-30.79%
Free cash flow per share (TTM)
-167.50%
Growth
Earnings per share change (TTM)
-16.79%
3-year earnings per share growth (CAGR)
-31.13%
What the Analysts think about ATXS
Analyst ratings (Buy, Hold, Sell) for Astria Therapeutics stock.
Bulls say / Bears say
Astria Therapeutics' STAR-0215 has demonstrated promising results in reducing hereditary angioedema (HAE) attack rates by 90-95% in the ALPHA-STAR trial, indicating strong potential for market approval and adoption. (BioSpace)
The company's robust cash position of $328.1 million as of December 31, 2024, is expected to fund operations into mid-2027, providing financial stability for ongoing and future projects. (StockTitan)
Analyst upgrades, such as Oppenheimer raising the price target from $26.00 to $28.00 and maintaining an 'outperform' rating, reflect positive sentiment and confidence in the company's growth prospects. (American Banking and Market News)
Astria Therapeutics reported a net loss of $94.3 million for the full year 2024, highlighting ongoing financial challenges and the need for successful product commercialization. (StockTitan)
The company's operating expenses increased significantly, with research and development expenses rising to $77.1 million and general and administrative expenses to $34.5 million in 2024, which may impact profitability if revenues do not materialize as expected. (StockTitan)
Despite positive trial results, the anticipated timeline for STAR-0215's Phase 3 trial completion and potential market entry extends into early 2027, which may delay revenue generation and affect investor patience. (BioSpace)
Data summarised monthly by Lightyear AI. Last updated on 12 Jun 2025.
ATXS Financial Performance
Revenues and expenses
ATXS Earnings Performance
Company profitability
ATXS News
AllArticlesVideos
Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit
Business Wire·1 week ago
Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress
Business Wire·2 weeks ago
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Astria Therapeutics stock?
Astria Therapeutics (ATXS) has a market cap of $307M as of June 28, 2025.
What is the P/E ratio for Astria Therapeutics stock?
The price to earnings (P/E) ratio for Astria Therapeutics (ATXS) stock is 0 as of June 28, 2025.
Does Astria Therapeutics stock pay dividends?
No, Astria Therapeutics (ATXS) stock does not pay dividends to its shareholders as of June 28, 2025.
When is the next Astria Therapeutics dividend payment date?
Astria Therapeutics (ATXS) stock does not pay dividends to its shareholders.
What is the beta indicator for Astria Therapeutics?
Astria Therapeutics (ATXS) has a beta rating of 0.45. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.